Saturday 17 October 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 1.89% and free cash flow fell 42.0%, each against the same quarter a year earlier.
29.52
0.01
+0.03%
Follow COGT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(147.70%) | (94.98%) | (108.39%) | (146.55%) | |
| (72.69%) | (51.99%) | (59.71%) | (68.00%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(86.51%) | (38.61%) | (42.94%) | (50.27%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.79) | (2.06) | (1.76) | (1.81) | |
Free Cash Flow |
(246.73) | (266.00) | (286.27) | (309.24) | |
Capital Expenditures |
(0.82) | (1.55) | (1.46) | (1.69) | |
| Other line items | |||||
Cash ROIC |
(33.45%) | (15.11%) | (16.87%) | (19.97%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(35.31) | (45.92) | (84.69) | (75.14) | |
Operating CF/Net income |
0.84 | 0.80 | 0.80 | 0.82 | |
Depreciation/Fixed assets |
(0.11) | 0.22 | 0.23 | 0.08 | |
Capex/Depreciation |
1.40 | (1.29) | (1.17) | (4.56) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.79) | (2.05) | (1.76) | (1.80) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates